Spoken Alpha
Opus Genetics, Inc.
Opus Genetics develops gene therapies to treat inherited retinal diseases and other ophthalmic disorders, with lead programs OPGx-LCA5 and OPGx-BEST1 in clinical trials. The company also markets phentolamine ophthalmic solution for mydriasis reversal and presbyopia, and is developing APX3330 for diabetic retinopathy.
Opus Genetics, Inc is a Healthcare company operating in Biotechnology with a $439.3M market cap.
IRD beat consensus EPS by 0.1% in Q2 FY2026, reported Aug 5, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add IRD, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for IRD.
$ curl https://api.spokenalpha.com/v1/companies/IRDFAQ
Spoken Alpha indexes IRD's earnings call transcripts at https://spokenalpha.com/companies/IRD. Each call links to attributed speakers and parsed analyst Q&A. Opus Genetics, Inc.'s own investor relations page is at https://ir.opusgtx.com/.
Opus Genetics, Inc. (IRD) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | $-0.14 | $-0.15 | +6.7% | $755.0K | — | — | EODHD |
| Q1 FY2026 | 2026-05-11 | $-0.75 | $-0.14 | -100.0% | $2.2M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-0.21 | $-0.12 | -78.3% | $3.9M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.25 | $-0.13 | -92.3% | $3.1M | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.12 | $-0.26 | +53.8% | $2.9M | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.32 | $-0.34 | +5.9% | $4.4M | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $-1.27 | $-0.05 | -100.0% | $4.3M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.29 | $-0.23 | -26.1% | $3.9M | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.30 | $-0.28 | -7.1% | $1.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-0.29 | $-0.14 | -100.0% | $1.7M | — | — | EODHD |
| Q4 FY2023 | 2024-03-07 | $-0.21 | $-0.05 | -100.0% | $1.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $0.25 | $-0.23 | +100.0% | $11.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-0.24 | $-0.24 | 0.0% | $3.7M | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.28 | $-0.16 | -75.0% | $1.7M | — | — | EODHD |
| Q4 FY2022 | 2023-03-29 | $1.69 | $1.00 | +69.0% | $39.9M | — | — | EODHD |
| Q3 FY2022 | 2022-11-03 | $-0.22 | $-0.29 | +24.1% | — | — | — | EODHD |
| Q2 FY2022 | 2022-08-11 | $-0.25 | $-0.33 | +24.2% | — | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-0.35 | $-0.35 | 0.0% | — | — | — | EODHD |
| Q4 FY2021 | 2022-03-23 | $-0.35 | $-0.35 | 0.0% | — | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-0.25 | $-0.36 | +30.6% | $489.0K | — | — | EODHD |
Source: EODHD. IRD reported actuals as published; sparse fields render as —.